Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03159195 · ClinicalTrials.gov registry record
Ibrance Real World Insights
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 652
- Enrollment target
NCT03159195: Completed study, sponsored by Pfizer.
NCT03159195 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 652 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03159195 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 652 participants
- Enrollment target
Study Summary
To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments in line with regional licensed indications in real world settings across multiple countries.
Primary Outcome
PFS was defined as the time from palbociclib combination treatment initiation until 1) clinician documented disease progression (PD) while on palbociclib, 2) death, 3) start of a new therapy line after final palbociclib dose, if the reason for discontinuation of palbociclib was disease progression, or 4) last available follow-up, whichever occurred first. Participants who did not experience a progression event (items 1, 2 and 3) were censored at date of last available follow-up. PFS (in months)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2021-06-24 |
What the finished NCT03159195 record still lists
NCT03159195 is an observational study that tracks outcomes without assigning an intervention. The registered 652 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03159195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03159195 about?
NCT03159195 is a clinical study titled "Ibrance Real World Insights". To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments in line with regional licensed indications in real world settings across multiple countries.
What is the current status of trial NCT03159195?
This trial is currently completed. The enrollment target is 652 participants. The study started on 2017-06-12. Estimated completion is 2021-06-24.
Who is sponsoring clinical trial NCT03159195?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI